• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Carbohydrate fatty acid monosulphate ester adjuvant enhances the immunogenicity of influenza antigens via TLR4/2-dependent mechanism

tetano

Editor, Senior Moderator
Front Immunol


. 2026 Mar 4:17:1787181.
doi: 10.3389/fimmu.2026.1787181. eCollection 2026.
Carbohydrate fatty acid monosulphate ester adjuvant enhances the immunogenicity of influenza antigens via TLR4/2-dependent mechanisms

Sruthi Vijaya Retnakumar[SUP] 1 [/SUP], Suraj Chandrabhan Singh[SUP] #[/SUP][SUP] 2 [/SUP], Srinivasa Reddy Bonam[SUP] #[/SUP][SUP] 3 4 [/SUP], Camille Chauvin[SUP] #[/SUP][SUP] 1 [/SUP], Mano Joseph Mathew[SUP] 5 6 [/SUP], Ida Busch Nielsen[SUP] 7 [/SUP], Christine Boyle[SUP] 8 [/SUP], Luuk Hilgers[SUP] 9 [/SUP], Max Søgaard[SUP] 7 [/SUP], Peter Paul Platenburg[SUP] 9 [/SUP], Jagadeesh Bayry[SUP] 1 2 [/SUP]


Affiliations
Abstract

Introduction: Subunit influenza vaccines require potent adjuvants to elicit robust and broad immune responses, particularly against emerging pandemic strains such as H7N9. However, currently approved adjuvants often fail to induce durable and broadly protective immunity. Carbohydrate fatty acid monosulphate ester (CMS), a synthetic glycolipid incorporated into a squalane-in-water emulsion, has demonstrated promising immunostimulatory properties and is currently undergoing phase I clinical evaluation. However, the molecular mechanisms underlying its adjuvanticity in human immune cells remain incompletely understood. We therefore investigated the immunological and molecular mechanisms by which CMS enhances influenza hemagglutinin (HA) immunogenicity.
Methods: Human peripheral blood mononuclear cells (PBMCs) and monocyte-derived dendritic cells (DCs) from healthy donors were stimulated with influenza HA antigen alone or in combination with CMS. Antigen-specific T cell responses were assessed using activation-induced marker assays and intracellular cytokine staining. DC maturation markers and cytokine secretion were analyzed by flow cytometry and ELISA. Antigen uptake was evaluated by fluorescence microscopy and flow cytometry. Bulk RNA sequencing of CMS-stimulated DCs was performed to identify differentially expressed genes and enriched pathways. Toll-like receptor (TLR) involvement was validated using THP-1 reporter assays and pharmacological inhibition in DCs.
Results: CMS significantly enhanced antigen-specific CD4⁺ and CD8⁺ T cell responses in PBMCs. While recombinant H7N9 HA alone poorly activated DCs, co-formulation with CMS induced robust upregulation of co-stimulatory molecules and pro-inflammatory cytokines, leading to a polyfunctional T helper cell response. Transcriptomic profiling revealed strong enrichment of TLR, NF-κB, JAK-STAT, and interferon signaling pathways. Functional studies confirmed that CMS-induced activation depends on TLR4 and TLR2 engagement.
Discussion: CMS enhances influenza antigen immunogenicity by promoting TLR4/2-dependent DC activation, inflammatory signaling, and improved antigen presentation. These findings define the mechanistic basis of CMS adjuvanticity and support its development as a promising adjuvant platform for next-generation influenza vaccines targeting emerging pandemic strains.

Keywords: T cells; adjuvants; carbohydrate fatty acid monosulphate ester; dendritic cells; influenza; toll-like receptors; vaccines.

 
Back
Top